OmarDzayeMD, MPH, PhDaAlexander C.RazaviMD, MPH, PhDabZeina A.DardariMSaLeslee J.ShawPhDcDaniel S.BermanMDdMatthew J.BudoffMDeMichael D.MiedemaMD, MPHfKhurramNasirMD, MPH, MScgAlanRozanskiMDhJohn A.RumbergerMD, PhDiCarl E.OrringerMDjSidney C.SmithJr.MDkRonBlanksteinMDlSeamus P.WheltonMD, MPHaMartin BødtkerMortensenMD, PhDamMichael J.BlahaMD, MPHa
doi : 10.1016/j.jacc.2021.08.019
Volume 78, Issue 16, 19 October 2021, Pages 1573-1583
There are currently no recommendations guiding when best to perform coronary artery calcium (CAC) scanning among young adults to identify those susceptible for developing premature atherosclerosis.
Tasneem Z.NaqviMD, MMMaTamar S.PolonskyMD, MSCIb
doi : 10.1016/j.jacc.2021.08.027
Volume 78, Issue 16, 19 October 2021, Pages 1584-1586
Matthew W.SegarMD, MSabMuhammad ShahzebKhanMD, MSccKershaw V.PatelMDdJavedButlerMD, MPH, MBAeW.H. WilsonTangMDfMuthiahVaduganathanMD, MPHgCarolyn S.P.LamMB, BS, PhDhSubodhVermaMD, PhDiDarren K.McGuireMD, MHScabAmbarishPandeyMD, MSCSa
doi : 10.1016/j.jacc.2021.08.020
Volume 78, Issue 16, 19 October 2021, Pages 1587-1598
Diabetes is associated with abnormalities in cardiac remodeling and high risk of heart failure (HF).
Vanita R.ArodaMDabPam R.TaubMDcAna MariaStantonMDab
doi : 10.1016/j.jacc.2021.08.026
Volume 78, Issue 16, 19 October 2021, Pages 1599-1602
Zhong-HeZhangMDab?HectorBarajas-MartínezPhDcde?HaoXiaMD, PhDabBianLiPhDfgJohn A.CapraPhDhJeromeClatotPhDiGan-XiaoChenMDabXiuChenMDabBoYangMD, PhDabHongJiangMD, PhDabGaryTseMD, PhDjkYoshiyasuAizawaMD, PhDlMichael H.GollobMDmMelvinScheinmanMDnCharlesAntzelevitchPhDcdeDanHuMD, PhDab
doi : 10.1016/j.jacc.2021.08.024
Volume 78, Issue 16, 19 October 2021, Pages 1603-1617
Two major forms of inherited J-wave syndrome (JWS) are recognized: early repolarization syndrome (ERS) and Brugada syndrome (BrS).
Elijah R.BehrMA, MBBS, MD
doi : 10.1016/j.jacc.2021.09.003
Volume 78, Issue 16, 19 October 2021, Pages 1618-1620
MatthiasUnterhuberMDa?Karl-PatrikKresojaMDa?Karl-PhilippRommelMDaChristianBeslerMDaAndreaBaragettiPhDbNoraKlötingDr.cdUtaCeglarekDr.eMatthiasBlüherMDcdMarkusScholzDr.fgAlberico L.CatapanoPhDbHolgerThieleMDaPhilippLurzMD, PhDa
doi : 10.1016/j.jacc.2021.08.018
Volume 78, Issue 16, 19 October 2021, Pages 1621-1631
Individualized risk prediction represents a prerequisite for providing personalized medicine.
Jean-SébastienHulotMD, PhDabPaulCloptonMSc
doi : 10.1016/j.jacc.2021.08.043
Volume 78, Issue 16, 19 October 2021, Pages 1632-1634
Azita H.TalasazPharmDabcParhamSadeghipourMDdMaryamAghakouchakzadehPharmDaIsaacDreyfusMDeHessamKakavandPharmDaHamidAriannejadMDbAakritiGuptaMD, MSefgMahesh V.MadhavanMD, MSefBenjamin W.Van TassellPharmDchDavidJimenezMD, PhDiManuelMonrealMD, PhDjMuthiahVaduganathanMD, MPHkJohnFanikosRPh, MBAlDave L.DixonPharmDchGregoryPiazzaMD, MSkSahil A.ParikhMDefDeepak L.BhattMD, MPHkGregory Y.H.LipMDmnGregg W.StoneMDfoHarlan M.KrumholzMD, SMgpqPeterLibbyMDkSamuel Z.GoldhaberMDkBehnoodBikdeliMD, MSfgk
doi : 10.1016/j.jacc.2021.08.021
Volume 78, Issue 16, 19 October 2021, Pages 1635-1654
Coronavirus disease-2019 (COVID-19) is associated with systemic inflammation, endothelial activation, and multiorgan manifestations. Lipid-modulating agents may be useful in treating patients with COVID-19. These agents may inhibit viral entry by lipid raft disruption or ameliorate the inflammatory response and endothelial activation. In addition, dyslipidemia with lower high-density lipoprotein cholesterol and higher triglyceride levels portend worse outcomes in patients with COVID-19. Upon a systematic search, 40 randomized controlled trials (RCTs) with lipid-modulating agents were identified, including 17 statin trials, 14 omega-3 fatty acids RCTs, 3 fibrate RCTs, 5 niacin RCTs, and 1 dalcetrapib RCT for the management or prevention of COVID-19. From these 40 RCTs, only 2 have reported preliminary results, and most others are ongoing. This paper summarizes the ongoing or completed RCTs of lipid-modulating agents in COVID-19 and the implications of these trials for patient management.
Amit R.PatelMDabMichaelSalernoMD, PhD, MScdeRaymond Y.KwongMD, MPHfAmitaSinghMDaBobakHeydariMDgChristopher M.KramerMDcd
doi : 10.1016/j.jacc.2021.08.022
Volume 78, Issue 16, 19 October 2021, Pages 1655-1668
Stress cardiovascular magnetic resonance imaging (CMR) is a cost-effective, noninvasive test that accurately assesses myocardial ischemia, myocardial viability, and cardiac function without the need for ionizing radiation. There is a large body of literature, including randomized controlled trials, validating its diagnostic performance, risk stratification capabilities, and ability to guide appropriate use of coronary intervention. Specifically, stress CMR has shown higher diagnostic sensitivity than single-photon emission computed tomography imaging in detecting angiographically significant coronary artery disease. Stress CMR is particularly valuable for the evaluation of patients with moderate to high pretest probability of having stable ischemic heart disease and for patients known to have challenging imaging characteristics, including women, individuals with prior revascularization, and those with left ventricular dysfunction. This paper reviews the basics principles of stress CMR, the data supporting its clinical use, the added-value of myocardial blood flow quantification, and the assessment of myocardial function and viability routinely obtained during a stress CMR study.
JananiRangaswamiMDKevin BryanLoMDMuthiahVaduganathanMD, MPHRoy O.MathewMD
doi : 10.1016/j.jacc.2021.08.025
Volume 78, Issue 16, 19 October 2021, Pages 1669-1670
Janice B.SchwartzMDScott C.KoganMDMargaret C.FangMD, MPH
doi : 10.1016/j.jacc.2021.06.056
Volume 78, Issue 16, 19 October 2021, Page e127
AntonioGómez-OutesMD, PhD, MSCPauAlcubillaMDRamónLecumberriMD, PhDGonzaloCalvo-RojasMD, PhDEmilioVargas-CastrillónPhD
doi : 10.1016/j.jacc.2021.07.059
Volume 78, Issue 16, 19 October 2021, Page e129
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟